Research programme: therapeutic HPV vaccines - Genkyotex

Drug Profile

Research programme: therapeutic HPV vaccines - Genkyotex

Alternative Names: GTL 002; Multivalent HPV vaccine - Genkyotex; ProEsovax

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BT PHARMA
  • Developer GENTICEL
  • Class Papillomavirus vaccines; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 29 Sep 2016 Research programme: therapeutic HPV vaccines - Genticel is available for licensing as of 29 Sep 2016. http://www.genticel.com/
  • 22 Sep 2016 Discontinued - Preclinical for Cervical cancer (Prevention) in France (Parenteral)
  • 22 Sep 2016 Discontinued - Preclinical for Human papillomavirus infections in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top